Business Context and Reporting Period
Company: Amneal Pharmaceuticals, Inc. (AMRX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A diversified, global biopharmaceutical company operating through three segments: Affordable Medicines (generics, injectables, biosimilars), Specialty (branded CNS and endocrine products), and AvKARE (government and institutional distribution). The company operates primarily in the U.S., India, and Ireland.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $3,018.8 million | $2,794.0 million |
| Gross Profit | $1,113.3 million | $1,020.4 million |
| Gross Margin | 36.9% | 36.5% |
| Operating Income | $394.1 million | $249.3 million |
| Net Income (Loss) | $127.9 million | ($73.9 million) |
| Net Income Attributable to Amneal | $72.1 million | ($116.9 million) |
| Diluted EPS | $0.22 | ($0.38) |
| Operating Cash Flow | $340.0 million | $295.1 million |
| Total Indebtedness | $2.7 billion | $2.5 billion |
| Cash and Cash Equivalents | $282.0 million | $110.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net revenue increased 8.0% year-over-year, driven by growth in all three segments. The Specialty segment saw an 18.6% increase, primarily due to CREXONT and UNITHROID sales. The AvKARE segment grew 12.3% due to government label channel expansion.
- Profitability Turnaround: The company returned to profitability, reporting net income of $127.9 million compared to a net loss of $73.9 million in 2024. This was significantly aided by a $96.7 million charge related to opioid litigation settlements recorded in 2024, which was absent in 2025.
- Legal Matters: In 2024, the company recorded a $96.7 million charge for a nationwide opioid settlement in principle. In 2025, this line item resulted in a credit of $0.4 million. The settlement became effective in January 2026, with initial payments made in Q1 2026.
- Debt Refinancing: In August 2025, the company refinanced its debt, issuing a $2.1 billion Term Loan Due 2032 and $600 million Senior Notes Due 2032. This resulted in a $31.4 million loss on refinancing in 2025.
- Impairment Charges: The company recognized $22.8 million in intangible asset impairment charges in 2025, primarily related to a Specialty segment product right following an FDA complete response letter.
Guidance, Outlook, and Risks
- Product Pipeline: The company continues to advance its respiratory platform and biosimilar portfolio. In December 2025, it received FDA approval for two denosumab biosimilars (Boncresa and Oziltus). It also launched the Brekiya autoinjector in October 2025.
- Collaborations: A collaboration with Metsera (acquired by Pfizer) was modified in early 2026, shortening the term but eliminating certain rebate obligations. The company also entered a strategic collaboration with ApiJect Systems for injectable manufacturing.
- Regulatory Risks: In August 2025, the FDA issued a Warning Letter to the company's manufacturing facility in Gujarat, India, classifying the inspection as "Official Action Indicated." The company is implementing corrective actions.
- Legal Contingencies: The company faces ongoing litigation regarding generic drug pricing, antitrust claims, and product liability (e.g., Ranitidine, Metformin). The nationwide opioid settlement, effective January 2026, involves payments totaling up to $136.9 million in cash and naloxone product over ten years.
- Tax Receivable Agreement (TRA): The company has an unrecorded contingent TRA liability of $129.1 million as of December 31, 2025, which could be recorded if deferred tax assets become realizable.
Key Facts for Investor Verification
- Opioid Settlement Payments: Verify the impact of the $23.8 million and $12.1 million installment payments made in January and February 2026 on 2026 liquidity and cash flow.
- FDA Warning Letter Resolution: Monitor the status of the corrective action plan for the Gujarat, India facility to ensure no production suspensions occur.
- Debt Service Obligations: Confirm the company's ability to service $2.7 billion in debt, including $193.9 million in expected interest payments for 2026, amidst variable interest rates.
- TRA Liability Trigger: Assess the likelihood of realizing deferred tax assets, which would trigger the recording of the $129.1 million contingent TRA liability.
- Customer Concentration: Note that four customers (Cencora, McKesson, Cardinal Health, CVS) accounted for approximately 71% of net revenue in 2025.